It’s all about healing.
EI.ventures is actively involved in all aspects of the budding psilocybin industry and the maturing NooTropic Cognitive Enhancement supplements market.
Our team is researching and developing methods of combining psychoactive compounds (such as DEA-registered psilocybin) with AI and blockchain technology to produce effective personalized bio-medicines, compounds, and formulas that enhance and optimize mental wellness.
We are acquiring permissions and licenses, both on a local and federal level, to establish a research lab focused on developing isolates of psilocybin at a reasonable cost so that more clinicians and scientists can conduct studies on the efficacy of treating a variety of mental health issues with the substance.
There is a rapidly increasing inventory of research papers and abstracts regarding the synthesis of Psilocybin and its analogues and homologues. Advances in the areas of traditional organic chemical synthesis, bio synthesis and enzymatic synthesis processes are driving this research.
The primary goal of these efforts are to lower the cost of synthesizing psilocybin and other relevant psycho active compounds so clinicians more broadly study the efficacy of proposed treatments. These advances are similar to those made in synthesizing antibiotics for wider and more cost-effective distribution, as well as more recent advances in the manipulation of yeast and RNA production in THC and CBD products.
The results of these studies are openly published and are easily obtained from academic research databases and from organizations such as the National Institute of Mental Health in the United States. The growing knowledge base regarding the brain chemistry involved in mental health and wellness are fueling these efforts world wide.
What we are doing
We continue to identify and align with licensed chemists and labs iIn the traditional fields of organic and bio chemistry as well as (so-called) kitchen chemists who have been innovating underground processes for years. Our primary goal is to quickly bring to market a so-called “1 pot” synthesis of relevant psychoactive materials or compounds. “1 pot” synthesis involves combining the fundamental components in simple combinations, adding bio active yeasts, enzymes, bio neutral solvents and allowing the targeted materials to better self-organize so less refinement is necessary to purge toxic lab solvents usually used in traditional synthetic lab processes.
Key Psilocybin figures and statistics
Across the globe, an estimated 300 million people have depression and around 60 million people suffer from bipolar disorder.
In 2018, researchers from Johns Hopkins University recommended that psilocybin be legalized for medical use.
Oregon is circulating a statewide ballot initiatives to legalize psilocybin for medical use or decriminalize psilocybin for all use.
California has a broader initiative that decriminalized all psilocybin use. Both of these statewide initiatives will be put to the voters in 2020.
Denver and Oakland recently approved the decriminalization of psilocybin in May and June of 2019.
In late 2018, the FDA upgraded psilocybin to "breakthrough therapy" status, meaning the FDA has acknowledged its potential and vowed to expedite its review process.
Formulate and synthesize a product of Psilocybin for higher efficacy and less side effects for the treatments of depression.
Use evidence based medicine approaches within IRB (institutional review boards) for studying and refining therapies.
Formulate and synthesize a Psilocybin-based compound to aid in mental thought and intellectual expansion for individuals.
Acquire and maintain DEA-licensed partnership for manufacturing and study applications while streamlining efficient and timely end user use through FDA drug licensing and development of legal State level avenues. i.e. state-level legal cannabis.
A report issued in 2018 by The Lancet Commission states that mental health disorders could cost the global economy up to $16 trillion by the year 2030 if the problems are not addressed.
Form a team of leading medical and business oriented researchers for process implementation of evidence based medical principles.
Form, purchase, or partner with an entity with a lab offering schedule 1 DEA access to psilocybin and its chemical derivatives.
This business arrangement should be in a state poised to expand legal access to psilocybin i.e. Colorado, Oregon or California.
Form or employ a lobbyist network for facilitation of legality and work ability of business model.
Work with IRB’s(Institutional Review Boards) for validation of study protocols for legitimate medical use, safety and efficacy.
Supply end users first through a dispensary model and grow partnerships with the medical community for use of products with acute emotional issue in out-patient and inpatient settings.